Recent advances in minimally invasive biomarkers of OSCC: from generalized to personalized approach
- PMID: 39157206
- PMCID: PMC11327221
- DOI: 10.3389/froh.2024.1426507
Recent advances in minimally invasive biomarkers of OSCC: from generalized to personalized approach
Abstract
Oral cancer is the 6th most common type of cancer worldwide, and oral squamous cell carcinoma (OSCC) accounts for >90% of oral cancers. It is a major health problem, particularly in low- and middle-income countries (LMICs), due to both its high incidence and significant mortality and morbidity. Despite being a global burden, and even with the significant advancement in the management of OSCC, the overall outcome of the disease is still abysmal. With the advent of time, advanced diagnostic and treatment approaches have come into practice, but the burden of the disease has not improved significantly. Major reasons attributed to the poor outcome are delay in diagnosis, locoregional recurrence and resistance to the currently available treatment regimen. In this review, we have highlighted the existing challenges in the diagnosis and have emphasized the advancements in minimally invasive biomarkers. Additionally, the importance of collaborative multidimensional approaches involving clinicians and researchers has been discussed, as well as the need to redefine and establish better utility and management of existing diagnostic and treatment protocols along with the minimally invasive/non-invasive biomarkers.
Keywords: circulating tumour DNA (ctDNA); circulating tumour cell (CTC); genomic biomarkers; minimally invasive biomarker; oral squamous cell carcinoma (OSCC); proteomic biomarker.
© 2024 Suri, Boora, Kaur, Chauhan, Ghoshal and Pal.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Emerging histological and serological biomarkers in oral squamous cell carcinoma: Applications in diagnosis, prognosis evaluation and personalized therapeutics (Review).Oncol Rep. 2023 Dec;50(6):213. doi: 10.3892/or.2023.8650. Epub 2023 Oct 20. Oncol Rep. 2023. PMID: 37859591 Free PMC article. Review.
-
Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives.Front Physiol. 2019 Dec 10;10:1476. doi: 10.3389/fphys.2019.01476. eCollection 2019. Front Physiol. 2019. PMID: 31920689 Free PMC article. Review.
-
Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma.J Biomed Sci. 2023 Aug 9;30(1):65. doi: 10.1186/s12929-023-00953-z. J Biomed Sci. 2023. PMID: 37559138 Free PMC article. Review.
-
Circulating biomarkers in oral cancer: Unravelling the mystery.J Oral Maxillofac Pathol. 2022 Jul-Sep;26(3):300-306. doi: 10.4103/jomfp.jomfp_338_22. Epub 2022 Oct 17. J Oral Maxillofac Pathol. 2022. PMID: 36588829 Free PMC article.
-
Gastric Resection for Malignancy.2024 May 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2024 May 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 32809595 Free Books & Documents.
References
-
- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clinicians. (2024) 74(3):229–63. - PubMed
-
- Early Detection, Prevention, and Infections Branch (EPR). (2023). Available online at: https://www.iarc.who.int/branches-epr (cited April 11, 2011).
-
- Department of Health. UK Chief Medical Officers' Alcohol Guidelines Review. (2016). Available online at: https://assets.publishing.service.gov.uk/media/5a7f51b4e5274a2e87db5206/... (Accessed April 11, 2024).
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources